Loss of Endogenous HMGB2 Promotes Cardiac Dysfunction and Pressure Overload-Induced Heart Failure in Mice
Michio SatoKeishi MiyataZhe TianTsuyoshi KadomatsuYoshihiro UjiharaJun MorinagaHaruki HoriguchiMotoyoshi EndoJiabin ZhaoShunshun ZhuTaichi SugizakiKimihiro IgataMasashi MuramatsuTakashi MinamiTakashi ItoMarco E. BianchiSatoshi MohriKimi ArakiKoichi NodeYuichi Oike
19
Citation
28
Reference
10
Related Paper
Citation Trend
Abstract:
Background: The rapid increase in the number of heart failure (HF) patients in parallel with the increase in the number of older people is receiving attention worldwide. HF not only increases mortality but decreases quality of life, creating medical and social problems. Thus, it is necessary to define molecular mechanisms underlying HF development and progression. HMGB2 is a member of the high-mobility group superfamily characterized as nuclear proteins that bind DNA to stabilize nucleosomes and promote transcription. A recent in vitro study revealed that HMGB2 loss in cardiomyocytes causes hypertrophy and increases HF-associated gene expression. However, it's in vivo function in the heart has not been assessed.Keywords:
Pressure overload
Loss function
Pressure overload
Ventricular hypertrophy
Cite
Citations (0)
Protein posttranslational modifications (PTMs) by O-linked β-N-acetylglucosamine (O-GlcNAc) rise during pressure-overload hypertrophy (POH) to affect hypertrophic growth. The hexosamine biosynthesis pathway (HBP) branches from glycolysis to make the moiety for O-GlcNAcylation. It is speculated that greater glucose utilization during POH augments HBP flux to increase O-GlcNAc levels; however, recent results suggest glucose availability does not primarily regulate cardiac O-GlcNAc levels. We hypothesize that induction of key enzymes augment protein O-GlcNAc levels primarily during active myocardial hypertrophic growth and remodeling with early pressure overload. We further speculate that downregulation of protein O-GlcNAcylation inhibits ongoing hypertrophic growth during prolonged pressure overload with established hypertrophy. We used transverse aortic constriction (TAC) to create POH in C57/Bl6 mice. Experimental groups were sham, 1-week TAC (1wTAC) for early hypertrophy, or 6-week TAC (6wTAC) for established hypertrophy. We used western blots to determine O-GlcNAc regulation. To assess the effect of increased protein O-GlcNAcylation with established hypertrophy, mice received thiamet-g (TG) starting 4 weeks after TAC. Protein O-GlcNAc levels were significantly elevated in 1wTAC versus Sham with a fall in 6wTAC. OGA, which removes O-GlcNAc from proteins, fell in 1wTAC versus sham. GFAT is the rate-limiting HBP enzyme and the isoform GFAT1 substantially rose in 1wTAC. With established hypertrophy, TG increased protein O-GlcNAc levels but did not affect cardiac mass. In summary, protein O-GlcNAc levels vary during POH with elevations occurring during active hypertrophic growth early after TAC. O-GlcNAc levels appear to be regulated by changes in key enzyme levels. Increasing O-GlcNAc levels during established hypertrophy did not restart hypertrophic growth.
Cite
Citations (16)
Introduction: Myocardial cyclic GMP (cGMP) elevation and activation of cGMP-dependent protein kinase (PKG) have been shown to attenuate pathological cardiac hypertrophy and remodeling. Expression o...
Pressure overload
Phosphodiesterase inhibitor
Myocardial hypertrophy
Cite
Citations (0)
Pressure overload
Cite
Citations (0)
Pressure overload
Concentric hypertrophy
Ventricular remodeling
Cite
Citations (38)
Pressure overload
Cite
Citations (0)
Pressure overload
Constriction
Cite
Citations (1)
Pressure overload
Ventricular hypertrophy
Myocardial fibrosis
Hydroxyproline
Cite
Citations (3)
Pressure overload
Concentric hypertrophy
Volume overload
Cite
Citations (114)